Abstract:Abstract Abstract 4419 Chronic myelogenous leukemia (CML) is characterized by the t(9;22) chromosomal translocation, which results in the generation of Bcr-Abl oncogene that encodes the chimeric Bcr-Abl protein with constitutive tyrosine kinase activity. Despite the great success of imatinib therapy in CML, not all patients, especially those in the accelerated or blastic phase, experience an optimal response to this drug or even to the more potent, second-generation TKIs. The emergence of resistance to TKIs has also become a significant problem implying that physiopathologically relevant cellular targets should be validated, such as NF-kappaB (NF-kB). Here we describe the activity of alantolactone, a small natural compound and see its effect on K562-sensitive (K562s, sensitive to imatinib) and K562-resistant (K562r, resistant to imatinib) cells. Results: Firstly, we used CCK-8 assay to determine the cell viability and found that K562s were inhibited up to 64.5% after 48 hours of incubation of 10uM concentration of alantolactone, Annexin V+ cells were up to 68% which were confirmed by morphological observation, and apoptosis-related proteins were activated during the treatment, suggesting its inducing-apoptosis ability. Secondly, incubation of alantolactone could inhibit NF-kB signaling activity, proved by inhibition of IkBa phosphorylation and blockade of nuclear translocation of p65, while the luciferase assay further revealed the inhibited transcription of NF-kB dependent reporter gene, which was confirmed by immunofluorescence staining. Of note, Bcr-Abl protein was specifically and rapidly down-regulated as early as 6 hours after 10uM of alantolactone treatment. And alantolactone-induced Bcr-Abl down-regulation could be partially reversed by the autophagy inhibitor chloroquine but not by the proteasome inhibitor MG132 or bortezomib, indicating that autophagy may contributes to Bcr-Abl reduction. Furthermore, similar concentration of alantolactone could also induce apoptosis in K562r cells and inhibited the growth of primary CD34+ leukemic cells from CML patients. Collectively, our results primarily demonstrated that alantolactone could induce apoptosis in CML cells, regardless of imatinib-sensitive or -resistant, by inhibiting NF-kB signaling and depleting Bcr/Abl through a unique mechanism. Alantolactone could be used as a probe for deciphering the mechanism of Bcr-Abl destruction and NF-kB inhibition, and this agent may be a promising candidate for treating CML patients. Disclosures: No relevant conflicts of interest to declare.

Growth Inhibition Effects of Isoalantolactone on K562/A02 Cells: Caspase-Dependent Apoptotic Pathways, S Phase Arrest, and Downregulation of Bcr/Abl

The Antiproliferation Effect of Berbamine on K562 Resistant Cells by Inhibiting NF‐κB Pathway

[Effects of Berbamine on K562 Cells and Its Mechanisms in Vitro and in Vivo].

Alantolactone Induces Apoptosis and Cell Cycle Arrest on Lung Squamous Cancer Sk-Mes-1 Cells

Linalool Inhibits the Growth of Human T Cell Acute Lymphoblastic Leukemia Cells with Involvement of the MAPK Signaling Pathway

Isoalantolactone induces apoptosis through reactive oxygen species-dependent upregulation of death receptor 5 in human esophageal cancer cells.

Isoalantolactone mediates the degradation of BCR-ABL protein in imatinib-resistant CML cells by down-regulating survivin

Isoalantolactone Inhibits Esophageal Squamous Cell Carcinoma Growth Through Downregulation of MicroRNA-21 and Derepression of PDCD4

Alantolactone induces apoptosis in chronic myelogenous leukemia sensitive or resistant to imatinib through NF-κB inhibition and Bcr/Abl protein deletion

Isoalantolactone inhibits the proliferation of human liver cancer cells by inducing intrinsic apoptosis

Alantolactone Induces Apoptosis in Imatinib-Sensitive and -Resistant CML Cells by Inhibiting NF-KappaB Signaling and Degrading Bcr/Abl Protein

Isoalantolactone Induces Intrinsic Apoptosis Through P53 Signaling Pathway in Human Lung Squamous Carcinoma Cells.

Alantolactone Induces Activation of Apoptosis in Human Hepatoma Cells.

11, 13-Dehydro Lactone Moiety in Gynecologic Cancer Cells

Isoalantolactone Induces Reactive Oxygen Species Mediated Apoptosis In Pancreatic Carcinoma Panc-1 Cells

CBL0137 Administration Suppresses Human Hepatocellular Carcinoma Cells Proliferation and Induces Apoptosis Associated with Multiple Cell Death Related Proteins.

Oleanen Induces Apoptosis of Cervical Cancer Cells by Up-Regulation of Bim

Alantolactone Induces Apoptosis in RKO Cells Through the Generation of Reactive Oxygen Species and the Mitochondrial Pathway

Inhibitory Effects of Natural Compound Alantolactone on Human Non-small Cell Lung Cancer A549 Cells

Alantolactone Induces Apoptosis Through ROS-mediated AKT Pathway and Inhibition of PINK1-mediated Mitophagy in Human HepG2 Cells.

Apoptosis induction by alantolactone in breast cancer MDA-MB-231 cells through reactive oxygen species-mediated mitochondrion-dependent pathway